BTIG reiterates Buy on Oric Pharmaceuticals with $26 target
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
BTIG Research reiterated a "Buy" rating on Oric Pharmaceuticals (NASDAQ:ORIC) with a $26 price target, implying significant upside from the $7.52 share price. Analyst coverage stands at 14 Buy, 1 Hold and no Sell ratings. The clinical-stage cancer drug developer reported a quarterly loss wider than expected, and its CFO sold a substantial number of shares in August.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.